TriangleNCT03539536 · CITED IN SOURCE DOCUMENTS
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2025-11-05
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Have locally advanced or metastatic non-small cell lung cancer (NSCLC). * Have c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory. Participant must submit archival or fresh tumor material for assessment of c-Met levels during the prescreening period. Tumor material from the primary tumor site and/or metastatic sites are allowed. If archival tissue is negative for c-Met overexpression, subject can submit fresh biopsy material for reassessment of c-Met expression. * Histologically documented non-squamous epidermal growth factor receptor (EGFR) wild type NSCLC (site documented EGFR status). Of note, subjects with other actionable mutations are eligible as long as EGFR status is known and all other eligibility criteria are met. As of Protocol Version 11, Stage 1 is complete and Stage 2 is enrolling participants with non-squamous EGFR wild type NSCLC only. * Must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting. * Multiple lines of tyrosine kinase inhibitors (TKIs) targeting the same tyrosine kinase (TK) count as 1 line of therapy for the purposes of this eligibility criterion. * Progressed on systemic cytotoxic therapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible), and prior anticancer therapies targeting driver gene alterations (if applicable). * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. * Treatment with any therapies within the noted time intervals is excluded prior to the first dose of telisotuzumab vedotin as noted in the protocol. * Metastases to the central nervous system (CNS) are eligible only after definitive therapy (such as surgery or radiotherapy) is provided within the protocol. Exclusion Criteria: * Have received radiation therapy to the lungs \< 6 months prior to the first dose of telisotuzumab vedotin. * Have received any live vaccine within 30 days of the first dose of investigational product. * Has adenosquamous histology. * Have a history of other malignancies except those noted within the protocol. * Have a history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids. * Have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD within 3 months of the planned first dose of the study drug (Except for Sites in Ireland). For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor. * For Sites in Ireland Only: Must not have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD. For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor. * Have a clinically significant condition(s) as noted in the protocol. * Have unresolved clinically significant adverse events of Grade \>= 2 from prior anticancer therapy, except for alopecia or anemia. * Have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin. * For Sites in France and Czech Republic Only: Have the following: * Known human immunodeficiency virus (HIV) infection. Note: HIV testing is not required for eligibility for this protocol unless mandated by local regulatory authority or ethics committee/institutional review board. * Active hepatitis B virus (HBV) infection, defined by hepatitis B surface antigen (HBsAg) positivity or HBV DNA \>= 500 IU/mL. In participants with known HBV infection, the presence of active infection must be tested locally. If HBV status is unknown, it must be tested locally at screening. * Active hepatitis C virus (HCV) infection, defined by HCV ribonucleic acid (RNA) positivity. Participants cured of HCV infection may be included in the study. In participants with known HCV infection, the presence of active infection must be tested locally. If HCV status is unknown, it must be tested locally at screening. * Uncontrolled autoimmune disease.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
- intervention Names
- Drug: Telisotuzumab vedotin
- label
- Telisotuzumab vedotin
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Telisotuzumab vedotin
- description
- Intravenous (IV) infusion
- name
- Telisotuzumab vedotin
- other Names
- ABBV-399
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 270
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
- measure
- Overall Response Rate (ORR) (Stage 1 and Stage 2)
- time Frame
- Up to approximately 3 years
- description
- An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
- measure
- Number of Participants with Adverse Events (Alternate dose cohort)
- time Frame
- Up to approximately 3 years
- secondary Outcomes
- description
- DoR is defined as the time from the participant's initial response (CR or PR) to the first occurrence of radiographic progression determined by an independent central review or death from any cause for the responders.
- measure
- Duration of Response (DoR) (Stage 1 and Stage 2)
- time Frame
- Up to approximately 3 years
- description
- DCR is defined as the percentage of participants with best overall response of confirmed CR, confirmed PR, or stable disease (SD) for at least 12 weeks following enrollment, based on RECIST, version 1.1.
- measure
- Disease Control Rate (DCR) (Stage 1 and Stage 2)
- time Frame
- Up to approximately 3 years
- description
- PFS is defined as the time from the participant's first dose of study drug until the first occurrence of radiographic progression determined by an independent central review or death from any cause.
- measure
- Progression-Free Survival (PFS) (Stage 1 and Stage 2)
- time Frame
- Up to approximately 3 years
- description
- OS is defined as the time from the participant's first dose of study drug until death from any cause.
- measure
- Overall Survival (OS) (Stage 1 and Stage 2)
- time Frame
- Up to approximately 3 years
Full study description
- brief Summary
- This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).
Source references
- references
- citation
- Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Cicin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. eCollection 2026 Jul.
- pmid
- 42368479
- type
- DERIVED
- citation
- Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6.
- pmid
- 38843488
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-4b61308f1456da2f4dbe
- requested nct id
- NCT03539536
- primary nct id
- NCT03539536
- source kind
- fda_approval_notice
- source record id
- fda-2f7de233a4d4da06
- source file sha256
- 404679639a43db6cd6d7d4f7c22e9ed8a99f79d296fc72e37771b58c06939c14
- payload sha256
- 7005b31024a0256364916a6804aea359ad6f55ccab831677e9910d230cd32184
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-4b61308f1456da2f4dbe
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03539536
- occurrences
- context exact
- elis will be posted on <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">Drugs@FDA</a>.</p><p>Efficacy was evaluated in the LUMINOSITY study (NCT03539536), a multicenter, open label, multi-cohort trial. The trial included 84 patients with epidermal growth factor receptor (EGFR) wild-type, non-squamous NSCLC with
- end
- 25352
- exact text
- NCT03539536
- start
- 25341
- offset unit
- unicode_code_points
- source event date
- 2025-05-14
- source file
- /tmp/cancer-full-research/updates/pages/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression.html
- source file sha256
- 404679639a43db6cd6d7d4f7c22e9ed8a99f79d296fc72e37771b58c06939c14
- source json pointer
- Source null
- source kind
- fda_approval_notice
- source record id
- fda-2f7de233a4d4da06
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 404679639a43db6cd6d7d4f7c22e9ed8a99f79d296fc72e37771b58c06939c14
- source title
- FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-f00d55d06f3ac5d79b3d
- requested nct id
- NCT03539536
- primary nct id
- NCT03539536
- source kind
- fda_spl_label
- source record id
- 998985bb-7cd1-4e80-bd08-8fc7c503f982
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 178233d213e4911f8c98250810351aa713a6c7a806d38e8e62fb416cfc43f6e4
- payload
- application numbers
- BLA761384
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-f00d55d06f3ac5d79b3d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03539536
- occurrences
- context exact
- sly Treated EGFR Wild-Type N on-squamous NSCLC with High c-Met Protein Overexpression LUMINOSITY The efficacy of EMRELIS was evaluated in the LUMINOSITY study (NCT03539536), a multicenter, open-label, single-arm, multi-cohort clinical trial. Eligible patients were required to have locally advanced or metastatic NSCLC with c-Met p
- end
- 198
- exact text
- NCT03539536
- start
- 187
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/58/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 998985bb-7cd1-4e80-bd08-8fc7c503f982
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 353560855c5721cc73275933c28e88c1f079e1175cb37e7d07a2e0e71072121c
- spl effective time
- 20250525
- spl set id
- bc04f980-3957-4e35-ab81-8ec2ffe87215
Preserved source evidence · Not medical advice